BeaconEquity.com announces investment report featuring Avanir Pharmaceuticals

BeaconEquity.com announces an investment report featuring Avanir Pharmaceuticals Inc. (Nasdaq:AVNR). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: http://www.beaconequity.com/i/AVNR

Get our alerts BEFORE the rest of the market. Follow us on Twitter: https://twitter.com/BeaconEquity

Avanir Pharmaceuticals Inc. (AVNR) engages in the development of therapeutic products for a variety of diseases primarily for the U.S. market. The Company has recently focused its resources to address the central nervous systems and inflammatory diseases markets. Avanir has one compound candidate, Zenvia, in phase III clinical trials. Zenvia is developed to treat pseudobulbar affect (PBA) and diabetic peripheral neuropathic pain (DPN pain). The Company has one commercialized product to treat cold sores, Abreva, marketed in the United States and Canada by GlaxoSmithKline Consumer Healthcare. 

In the report, the analyst notes:

"Avanir has one compound candidate, called Zenvia, in phase III clinical trials. Zenvia is developed to treat pseudobulbar affect (PBA) and diabetic peripheral neuropathic pain (DPN pain).

"Diabetes is a major therapeutic segment of the pharmaceutical industry, with global sales totaling more than $17 billion for 2005, up from $4 billion in sales for 1995. The pharmaceutical industry expects anti-diabetic drug therapies to grow to more than $22 billion by 2012 due to a growing population of aged persons.

"If ultimately approved by the U.S. Food and Drug Administration (FDA), the market for Avanir's drug candidate Zenvia could reach $500 million to more than $1 billion at its market saturation. Zenvia is in phase III clinical trials, with the prospects of commercialization reaching approximately 90% following successful completion of this phase of development."